Diagnosis and treatment of rosacea: State of the art

Journal of Drugs in Dermatology

Volumn 11, Issue 6, 2012, Pages 725-730

  Baldwin, Hilary E ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; RETINOIC ACID; SULFACETAMIDE; SULFUR; TETRACYCLINE; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; CANDIDIASIS; DEMODEX; DIARRHEA; ERYTHEMATOTELANGIECTATIC ROSACEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INNATE IMMUNITY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEUROPATHY; OCULAR ROSACEA; PAPULE; PAPULOPUSTULAR ROSACEA; PHOTOSENSITIVITY; PHYMATOUS ROSACEA; PROTEIN EXPRESSION; PUSTULE; RASH; REVIEW; ROSACEA; SEIZURE; SKIN IRRITATION; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; HUMANS; ROSACEA; TREATMENT OUTCOME;

EID: 84863537347     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Rolleston JD. A note on the early history of rosacea. Proc R Soc Med. 1933;26(4):327-329.
2. Rosacea riddle now threatens more than 16 million Americans [news release]. Chicago: National Rosacea Society; April 1, 2010. http://www.rosacea. org/press/archive/20100401.php. Accessed April 27, 2010.
3. Berg M, Lidén S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69(5):419-423. (Pubitemid 19226109)
4. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352(8):793-803.
5. Sobye P. Aetiology and pathogenesis of rosacea. Acta Derm Venereol. 1950;30(2):137-158.
6. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341; quiz 342-324.
7. Kelton Research. National rosacea first impressions survey. Chicago: National Rosacea Society; 2009.
8. Rebora A, Drago F, Parodi A. May Helicobacter pylori be important for dermatologists? Dermatology. 1995;191(1):6-8.
9. Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med. 1997;90(3):144-150. (Pubitemid 27135946)
10. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78(2):97-100. (Pubitemid 44433118)
11. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
12. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000;343(5):338-344.
13. Schauber J, Dorschner RA, Coda AB, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803-811. (Pubitemid 46348539)
14. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
15. Halder RM, Brooks HL, Callender VD. Acne in ethnic skin. Dermatol Clin. 2003;21(4):609-615, vii. (Pubitemid 38005076)
16. Starr PA, Macdonald A. Oculocutaneous aspects of rosacea. Proc R Soc Med. 1969;62(1):9-11.
17. Webster GF. Rosacea. Med Clin North Am. 2009;93(6):1183-1194.
18. Beutner KR, Lemke S, Calvarese B. A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential. Cutis. 2006;77(4 suppl):12-17. (Pubitemid 43723533)
19. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282(7):449-454. (Pubitemid 20350067)
20. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-414. (Pubitemid 38469243)
21. Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723-730. (Pubitemid 33032570)
22. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283(3):162-166.
23. Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Doubleblind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/ clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43(5):381-387. (Pubitemid 38714606)
24. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319-324. (Pubitemid 24107870)
25. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512; quiz 513-494.
26. Del Rosso JQ. Update from the Scientific Panel on Antibiotic Use in Dermatology: clinical correlations for the dermatologist. Cutis. 2008;82(2 suppl 2):3-4.
27. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25(2):127-132, v. (Pubitemid 46566394)
28. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1(7971):1211-1212.
29. Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102(4):443-445. (Pubitemid 10147030)
30. Schmidt JB, Gebhart W, Raff M, Spona J. 13-cis-Retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol. 1984;64(1):15-21. (Pubitemid 14179561)
31. Colgan R, Powers JH. Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. Am Fam Physician. 2001;64(6):999-1004. (Pubitemid 32900287)
32. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51(8):895-903.
33. Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66(4 suppl):7-13.
34. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139(4):467-471. (Pubitemid 36427611)
35. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol. 1998;139(53 suppl):4-8. (Pubitemid 29003259)
36. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265. (Pubitemid 43144395)
37. Fleishcher, A. Inflammation in Rosacea and acne vulgaris: Implications for patient care. J Drugs Dermatol. 2010;10(6):614-620.
38. Vibramycin (doxycycline) [package insert]. New York, NY: Pfizer Labs; 2011.
39. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79(3):440-452.
40. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576.
41. Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30 mg immediate-release and 10 mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(5 suppl):16-25.